Immunogenicity and predictors of response to a single dose trivalent seasonal influenza vaccine in multiple sclerosis patients receiving disease‐modifying therapies

To evaluate the immunogenicity and safety of a seasonal influenza vaccine in a cohort of multiple sclerosis (MS) patients receiving different immunomodulating/immunosuppressive therapies and assess predictors of immune response.

[1]  S. Klein,et al.  Sex-based biology and the rational design of influenza vaccination strategies. , 2014, The Journal of infectious diseases.

[2]  H. Olberg,et al.  Immunotherapies influence the influenza vaccination response in multiple sclerosis patients: an explorative study , 2014, Multiple sclerosis.

[3]  E. Clementi,et al.  Efficacy of vaccination against influenza in patients with multiple sclerosis: The role of concomitant therapies. , 2014, Vaccine.

[4]  U. Bergman,et al.  Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm, Sweden , 2011, BMJ : British Medical Journal.

[5]  J. Hillert,et al.  Hospital admission due to infections in multiple sclerosis patients , 2013, European journal of neurology.

[6]  Ashutosh Kumar Singh,et al.  Randomized trial of vaccination in fingolimod-treated patients with multiple sclerosis , 2015, Neurology.

[7]  W. Hop,et al.  Prospective study on the relationship between infections and multiple sclerosis exacerbations. , 2002, Brain : a journal of neurology.

[8]  M. Lopez-Bresnahan,et al.  Immune response to influenza vaccine is maintained in patients with multiple sclerosis receiving interferon beta-1a , 2005, Neurology.

[9]  J. Frederiksen,et al.  Vaccines and multiple sclerosis: a systematic review , 2017, Journal of Neurology.

[10]  R. Knobler,et al.  A multicenter, randomized, double-blind, placebo-controlled trial of influenza immunization in multiple sclerosis , 1997, Neurology.

[11]  H. Olberg,et al.  Antibody response to seasonal influenza vaccination in patients with multiple sclerosis receiving immunomodulatory therapy , 2018, European journal of neurology.

[12]  J. Correale,et al.  H1N1 vaccination does not increase risk of relapse in multiple sclerosis: a self-controlled case-series study , 2012, Multiple sclerosis.

[13]  Ruihua Yin,et al.  H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. , 2011, American journal of preventive medicine.

[14]  F. Jacques.  Defining the clinical course of multiple sclerosis: The 2013 revisions , 2015, Neurology.

[15]  B. Weinshenker,et al.  Atypical inflammatory demyelinating syndromes of the CNS , 2016, The Lancet Neurology.

[16]  J. Correale,et al.  Immunizations and risk of multiple sclerosis: systematic review and meta-analysis , 2011, Journal of Neurology.

[17]  L. Kappos,et al.  Preserved Antigen-Specific Immune Response in Patients with Multiple Sclerosis Responding to IFNβ-Therapy , 2013, PloS one.

[18]  Jorie M. Butler,et al.  Multiple Sclerosis and Risk of Infection-Related Hospitalization and Death in US Veterans. , 2015, International journal of MS care.

[19]  A. Compston,et al.  Multiple sclerosis , 2008, The Lancet.

[20]  A. Bar-Or,et al.  Teriflunomide effect on immune response to influenza vaccine in patients with multiple sclerosis , 2013, Neurology.

[21]  S Suissa,et al.  Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. , 2001, The New England journal of medicine.

[22]  B. Hemmer,et al.  Role of the innate and adaptive immune responses in the course of multiple sclerosis , 2015, The Lancet Neurology.

[23]  U. Zettl,et al.  Immune-mediated CNS diseases: a review on nosological classification and clinical features. , 2012, Autoimmunity reviews.

[24]  Hana Golding,et al.  Patients with MS under daclizumab therapy mount normal immune responses to influenza vaccination , 2016, Neurology: Neuroimmunology & Neuroinflammation.

[25]  J. Chataway,et al.  Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination , 2011, Journal of Neurology.

[26]  H. Lassmann.  Pathology and disease mechanisms in different stages of multiple sclerosis , 2013, Journal of the Neurological Sciences.

[27]  P. Sørensen,et al.  The changing demographic pattern of multiple sclerosis epidemiology , 2010, The Lancet Neurology.

[28]  H. Hartung,et al.  Vaccination against infection in patients with multiple sclerosis , 2012, Nature Reviews Neurology.

[29]  Recommended composition of influenza virus vaccines for use in the 2011-2012 northern hemisphere influenza season. , 2011, Releve epidemiologique hebdomadaire.

[30]  Christian Confavreux,et al.  The clinical course of multiple sclerosis. , 2014, Handbook of clinical neurology.

[31]  Stiko.  Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut – 2016/2017 , 2016 .

[32]  M. Schlüter,et al.  Antibody Response After a Single Dose of an AS03-Adjuvanted Split-Virion Influenza A (H1N1) Vaccine in Heart Transplant Recipients , 2011, Transplantation.

[33]  A. Karni,et al.  Seasonal and H1N1v influenza vaccines in MS: Safety and compliance , 2012, Journal of the Neurological Sciences.

[34]  J. Sejvar,et al.  Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. , 2011, Vaccine.

[35]  Jeffrey A. Cohen,et al.  Defining the clinical course of multiple sclerosis: the 2013 revisions. , 2014, Neurology.

[36]  B. Weinshenker,et al.  Disease modifying therapies for relapsing multiple sclerosis , 2016, British Medical Journal.

[37]  G. Pawelec,et al.  Age and immunity: What is “immunosenescence”? , 2017, Experimental Gerontology.

[38]  A. Svenningsson,et al.  Humoral immune response to influenza vaccine in natalizumab-treated MS patients , 2012, Neurological research.

[39]  Recommended viruses for influenza vaccines for use in the 2010-2011 northern hemisphere influenza season. , 2010, Releve epidemiologique hebdomadaire.

[40]  H. Hartung,et al.  Disease-modifying therapies and infectious risks in multiple sclerosis , 2016, Nature Reviews Neurology.

[41]  Safety and immunogenicity of a trivalent single dose seasonal influenza vaccine containing pandemic A(H1N1) antigen in younger and elderly subjects: a phase III open-label single-arm study. , 2011, Vaccine.